Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum's GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.

Location: 2710 Reed Road, Suite 160, Texas, 77051, US | Website: www.bellicum.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing